Highlights include an oral presentation on the safety and efficacy data from the ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis, at 152 weeks.¹ It will take place on Thursday, October 1, from 10:45-10:55 AM CET in Hall N. A second oral presentation will examine how itch, skin lesion severity, and conversely, treatment with Nemluvio impact sleep disturbance in patients with atopic dermatitis and prurigo nodularis, and will take place on Thursday, October 1, from 11:15-11:25 AM CET in Hall N.² Additional presentations will quantify the impact of itch and skin lesion severity on quality of life in atopic dermatitis and evaluate the long-term safety profile of Nemluvio over two years across the ARCADIA and OLYMPIA extension studies. An exploration of new real-world evidence characterizing patients with atopic dermatitis and prurigo nodularis receiving advanced systemic therapies, alongside a data-driven conceptual disease model designed to deepen understanding of disease burden and outcomes in prurigo nodularis, will also be presented at the congress.^3-7 Galderma will also host a symposium titled “Advancing treatment outcomes in atopic dermatitis and prurigo nodularis: Targeting the IL-31 neuroimmune pathways,” on Friday, October 2, from 1:00-2:00 PM CET in Hall C, Level 2. Featuring experts Dr. Sarina Elmariah, Dr. Andrew Pink, and Prof. Stephen Weidinger, the session will explore the burden of itch in atopic dermatitis and prurigo nodularis, the role of neuroimmune cytokines beyond itch and how advanced therapies can help improve patient outcomes and quality of life.